MRK - Merck & Co., Inc.

NYSE - NYSE Prix différé. Devise en USD

109,17

-1,90

(-1,71 %)

À la clôture : 04:03PM EDT

109,09

-0,08

(-0,07 %)

Échanges après Bourse :

06:06PM EDT

Le graphique des titres n’est pas pris en charge par votre navigateur actuel

Cap. boursière	277,012B
Bêta (mensuel sur 5 ans)	0,36
Rapport P/E (sur 12 mois)	21,32
BPA (sur 12 mois)	S.O.
Date de bénéfices	S.O.
Dividende et rendement à terme	2,92 (2,63 %)
Date ex-dividende	14 juin 2023
Objectif sur 1 an	S.O.

Communiqués de presse

ACCESSWIRE
MRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant